<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202499">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453440</url>
  </required_header>
  <id_info>
    <org_study_id>CNA109479</org_study_id>
    <nct_id>NCT00453440</nct_id>
  </id_info>
  <brief_title>Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701</brief_title>
  <official_title>Prospective Epidemiological Study of the Prevalence of HLA-B*5701 in HIV-1 Infected UK Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the prevalence of a genetic marker, HLA-B5701, in the UK
      population. HLA-B*5701 has been strongly associated with the risk of an allergic reaction to
      a HIV medicine, Abacavir. The allergic reaction is known as a hypersensitivity reaction.

      The study is a prospective study inviting HIV-1 positive patients over the age of 18 years
      to participate. Each participant will complete one study visit. They will be asked for
      details of their background including their age, sex, ethnicity, country of origin and
      parental country of origin.

      They will be asked to give two samples to test for the presence of the genetic marker
      HLA-B*5701. The two samples are:

        -  A cheek swab

        -  A blood sample

      In selected centres patients may be asked to provide up to two additional blood samples.
      These samples will be used to help develop and validate new methods of determining
      HLA-B*5701 testing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HLA-B*5701 in the UK population via central labs</measure>
    <time_frame>2 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HLA-B*5701 in major UK ethnotypes in the study population. Description of HLA-B*5701 in the UK population via local labs.</measure>
    <time_frame>2 Hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1569</enrollment>
  <condition>HIV Infection</condition>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cheek swab &amp; blood test</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  HIV-1 infected patients over 18 years of age

          -  Patient willing &amp; able to understand and provide written informed consent

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, BSc MBBS</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woolwich, London</city>
        <state>London</state>
        <zip>SE18 4QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>WS2 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>August 31, 2010</lastchanged_date>
  <firstreceived_date>March 28, 2007</firstreceived_date>
  <keyword>HIV</keyword>
  <keyword>HLA-B*5701</keyword>
  <keyword>Abacavir hypersensitivity reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
